Cerulean (CERU) Shares Up 4% On Phase 1b/2 CRLX101 Trial Results

Shares of Cerulean Pharma Inc. (CERU) are higher by more than 4% to $11.12 in after-hours trading on Thursday, after the company announced phase 1b/2 trial of CRLX101 in combination with Avastin in relapsed renal cell carcinoma met primary endpoint.

“The top-line results from this trial in a difficult-to-treat patient population are encouraging,” said in a statement Paul Friedman, M.D., Executive Chairman at Cerulean. “The median [progression free survival] PFS of 9.9 months supports the rationale for our ongoing randomized Phase 2 trial of CRLX101 plus Avastin in 3rd and 4th line RCC.”

Fundamentally, CERU shows the following financial data:

• $57.79 million in cash in most recent quarter
• $6.83 million t-12 total assets
• ($12.77) million total equity
• $86.00K t-12 revenue
• ($16.91) million annual net income
• ($16.62) million free cash flow

On valuation measures, Cerulean Pharma Inc. shares have a T-12 price/sales ratio of 2,159 and a price/book for the same period of 3.54. EPS is ($1.16). The name has a market cap of $203.93 million and a median Wall Street price target of $12.50 with a high target of $14.00. Currently there are 4 analysts that rate CERU a ‘Buy’. No analyst rates it a ‘Hold’ or a ‘Sell’.

In terms of share statistics, Cerulean Pharma Inc. has a total of 20.13 million shares outstanding with 55.51% held by insiders and 2.80% held by institutions. The stock’s short interest currently stands at 0.54%, bringing the total number of shares sold short to 45,458.

Shares of the Cambridge Massachusetts-based company are up 52.68% year-over-year and 48.39% year-to-date.

Cerulean Pharma Inc is a clinical-stage Cambridge, Massachusetts-based company that focuses on developing nanopharmaceutical product candidates in the areas of oncology and other diseases in the United States.

Create Content With AI

Try TradingView For Free

Risk Our Money Not Yours | Get 50% Off Any Account